6978 — Immunotech Biopharm Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.87bn
- HK$2.34bn
Annual balance sheet for Immunotech Biopharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 845 | 353 | 79.5 | 177 | 57.5 |
| Net Total Receivables | 0 | — | — | — | 0.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 884 | 412 | 118 | 214 | 87.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 154 | 427 | 527 | 501 | 452 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,210 | 1,098 | 879 | 846 | 564 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 31.6 | 180 | 208 | 203 | 430 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 82.7 | 275 | 371 | 673 | 577 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 1,128 | 822 | 508 | 174 | -13.3 |
| Total Liabilities & Shareholders' Equity | 1,210 | 1,098 | 879 | 846 | 564 |
| Total Common Shares Outstanding |